• Thurs news: Moderna targets $1.1B in R&D spending cuts. Gene therapy startup emerges. J&J leads $50M financing for imaging company. Sanofi gets into radioligands. GSK’s mRNA flu vax trial. See more on our front page

alzhemier's disease

  1. Biogen’s Alzheimer’s drug delayed; lack of clarity exists

    The analysts started scratching their heads during an earnings conference call as there was a lack of clarity in the delay in filing of Biogen's Alzheimer's drug. Last year, Biogen stock soared by 27% after the company optimistically said it would file an application with the US Food and Drug...
    • anonymous
    • Thread
    • alzhemier's disease biogen biogen alzheimer’s
    • Replies: 121
    • Forum: Biogen

  2. Alzheimer’s disease trial - Axsome Therapeutics reports positive outcome

    Axsome Therapeutics stock skyrockets on positive outcome from Alzheimer's disease trial https://news.alphastreet.com/axsome-therapeutics-nasdaq-axsm-stock-almost-doubles-on-positive-outcome-from-alzheimers-disease-trial-in-premarket/
    • anonymous
    • Thread
    • alzhemier's disease axsome therapeutics biopharma clinical trial dementia drug eli lilly fda merck pfizer
    • Replies: 0
    • Forum: Pharma/Biotech Companies - In the News

  3. Lilly partners with AC Immune

    Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease. Will it succeed and create a drug to cure Alzheimer's disease?
    • anonymous
    • Thread
    • ac immune agreement alzhemier's disease biogen collaboration eli lilly merck neurogenerative partnership pfizer
    • Replies: 3
    • Forum: Eli Lilly
Top Bottom
Back